Asensus Surgical Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Asensus Surgical de 52.1% y 47.1% respectivamente, mientras que el BPA crecerá en un 56.7% al año.

Información clave

52.1%

Tasa de crecimiento de los beneficios

56.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.5%
Tasa de crecimiento de los ingresos	47.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	26 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NYSEAM:ASXC - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	51	-24	N/A	N/A	1
12/31/2025	22	-55	N/A	N/A	2
12/31/2024	12	-62	N/A	N/A	2
12/31/2023	9	-78	-64	-64	N/A
9/30/2023	6	-79	-65	-64	N/A
6/30/2023	7	-80	-65	-64	N/A
3/31/2023	7	-79	-61	-60	N/A
12/31/2022	7	-76	-60	-59	N/A
9/30/2022	7	-74	-59	-58	N/A
6/30/2022	7	-71	-54	-52	N/A
3/31/2022	7	-64	-48	-46	N/A
12/31/2021	8	-62	-42	-41	N/A
9/30/2021	7	-60	-41	-40	N/A
6/30/2021	5	-59	-41	-40	N/A
3/31/2021	5	-60	-45	-44	N/A
12/31/2020	3	-60	-47	-47	N/A
9/30/2020	3	-60	-48	-48	N/A
6/30/2020	4	-143	-59	-59	N/A
3/31/2020	7	-149	-62	-62	N/A
12/31/2019	9	-154	-74	-73	N/A
9/30/2019	15	-147	-73	-72	N/A
6/30/2019	19	-69	-69	-69	N/A
3/31/2019	22	-83	-61	-60	N/A
12/31/2018	24	-62	-49	-48	N/A
9/30/2018	20	-131	-46	-45	N/A
6/30/2018	15	-150	-42	-41	N/A
3/31/2018	10	-130	-47	-46	N/A
12/31/2017	7	-145	-49	-47	N/A
9/30/2017	4	-83	N/A	-53	N/A
6/30/2017	5	-57	N/A	-50	N/A
3/31/2017	3	-122	N/A	-51	N/A
12/31/2016	2	-120	N/A	-52	N/A
9/30/2016	1	-120	N/A	-51	N/A
6/30/2016	N/A	-121	N/A	-50	N/A
3/31/2016	N/A	-50	N/A	-45	N/A
12/31/2015	N/A	-47	N/A	-39	N/A
9/30/2015	0	-41	N/A	-34	N/A
6/30/2015	0	-39	N/A	-36	N/A
3/31/2015	0	-40	N/A	-35	N/A
12/31/2014	0	-38	N/A	-33	N/A
9/30/2014	0	-38	N/A	-31	N/A
6/30/2014	1	-37	N/A	-27	N/A
3/31/2014	1	-31	N/A	-24	N/A
12/31/2013	1	-28	N/A	-21	N/A
9/30/2013	2	-24	N/A	-17	N/A
6/30/2013	2	-16	N/A	-13	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ASXC siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ASXC siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ASXC siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (47.1% al año) de ASXC crezcan más rápidamente que los del mercado US (7.9% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (47.1% al año) de ASXC crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ASXC se prevé que sea elevada dentro de 3 años.

Asensus Surgical Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 10%

Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023

Consensus EPS estimates fall by 23%

Consensus revenue estimates fall by 34%

Price target decreased by 21% to US$1.75

Asensus Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Recent updates

Asensus Surgical, Inc. to Report Q1, 2024 Results on May 14, 2024

KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. (NYSEAM:ASXC) for $100 million.

Full year 2023 earnings: EPS exceeds analyst expectations

Asensus Surgical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

President exercised options and sold US$131k worth of stock

Consensus revenue estimates increase by 10%

Asensus Surgical, Inc. Provides Unaudited Earnings Guidance for the Quarter and Full Year Ending on December 31, 2023

Asensus Surgical, Inc. Develops the LUNA Surgical System

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Asensus Surgical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Asensus Surgical, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New minor risk - Share price stability

Consensus EPS estimates fall by 23%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 34%

Price target decreased by 21% to US$1.75

Full year 2022 earnings: EPS exceeds analyst expectations

President exercised options and sold US$406k worth of stock

Asensus Surgical, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Insufficient new directors

Consensus revenue estimates fall by 17%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$2.25

Asensus Surgical, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Asensus Surgical, Inc. Announces Impairment Charges for Three Months Ended June 30, 2022

Asensus Surgical, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Asensus Surgical, Inc. to Showcase the Senhance Surgical System and Performance-Guided Surgery in Upcoming Society of Robotic and Digital Surgery Conference

Asensus Surgical, Inc., Annual General Meeting, Jun 14, 2022

Asensus Surgical, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Asensus Surgical, Inc. Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center

Asensus Surgical Receives FDA 510(k) Clearance for Expansion of Machine Vision Capabilities

Asensus Surgical, Inc. to Report Q4, 2020 Results on Mar 11, 2021

Asensus Surgical Announces FDA Clearance in General Surgery

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $69.249999 million.

TransEnterix, Inc. has completed a Follow-on Equity Offering in the amount of $31.25 million.

TransEnterix, Inc. Announces Southern Surgical Hospital to Initiate a Senhance Digital Laparoscopic Program

TransEnterix Announces Approval of Senhance Surgical System in Russian Federation

Transenterix, Inc. Does Not Provide Forward-Looking Guidance

TransEnterix, Inc. to Report Q3, 2020 Results on Nov 05, 2020

TransEnterix, Inc. Announces First Pediatric Surgical Cases with Senhance® Surgical System

TransEnterix Announces Toshima Hospital in Japan to Initiate A Senhance® Digital Laparoscopy Program

Transenterix, Inc. Not Provide Revenue Guidance

TransEnterix, Inc. Contemplates Bankruptcy

TransEnterix, Inc. to Report Q2, 2020 Results on Aug 05, 2020

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2000 Dynamic Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell Microcap Value Index

TransEnterix, Inc.(AMEX:TRXC) dropped from Russell 2500 Growth Index

TransEnterix, Inc.(AMEX:TRXC) dropped from S&P Global BMI Index

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento